

Global Adalimumab Monoclonal Antibody Biosimilar Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

https://marketpublishers.com/r/GDCF334A1BA5EN.html

Date: June 2023

Pages: 108

Price: US\$ 3,480.00 (Single User License)

ID: GDCF334A1BA5EN

Abstracts

According to our (Global Info Research) latest study, the global Adalimumab Monoclonal Antibody Biosimilar market size was valued at USD 433.2 million in 2022 and is forecast to a readjusted size of USD 955.4 million by 2029 with a CAGR of 12.0% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The introduction of Humira biosimilars is expected to increase competition in the market, leading to lower prices and improved access to treatment for patients. The availability of biosimilars provides an alternative option for healthcare providers and payers to choose from, potentially reducing the overall healthcare expenditure associated with biologic treatments.

Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.

This report is a detailed and comprehensive analysis for global Adalimumab Monoclonal Antibody Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:



Global Adalimumab Monoclonal Antibody Biosimilar market size and forecasts, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Adalimumab Monoclonal Antibody Biosimilar market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Adalimumab Monoclonal Antibody Biosimilar market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Adalimumab Monoclonal Antibody Biosimilar market shares of main players, shipments in revenue (\$ Million), sales quantity (K Units), and ASP (US\$/Unit), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Adalimumab Monoclonal Antibody Biosimilar

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Adalimumab Monoclonal Antibody Biosimilar market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Cadila Healthcare, Torrent Pharmaceuticals, Amgen, Boehringer Ingelheim and Novartis, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation

Adalimumab Monoclonal Antibody Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations



and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type		
	Syringe	
	Pen	
Market segment by Application		
	Ankylosing Spondylitis	
	Rheumatoid Arthritis	
	Crohn's Disease	
	Other	
Major players covered		
	Cadila Healthcare	
	Torrent Pharmaceuticals	
	Amgen	
	Boehringer Ingelheim	
	Novartis	
	Samsung Bioepis	
	Viatris	
	Pfizer	



Fresenius Kabi

Coherus

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Adalimumab Monoclonal Antibody Biosimilar product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Adalimumab Monoclonal Antibody Biosimilar, with price, sales, revenue and global market share of Adalimumab Monoclonal Antibody Biosimilar from 2018 to 2023.

Chapter 3, the Adalimumab Monoclonal Antibody Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Adalimumab Monoclonal Antibody Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.



Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Adalimumab Monoclonal Antibody Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.

Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.

Chapter 13, the key raw materials and key suppliers, and industry chain of Adalimumab Monoclonal Antibody Biosimilar.

Chapter 14 and 15, to describe Adalimumab Monoclonal Antibody Biosimilar sales channel, distributors, customers, research findings and conclusion.



Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope of Adalimumab Monoclonal Antibody Biosimilar
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Adalimumab Monoclonal Antibody Biosimilar Consumption

Value by Type: 2018 Versus 2022 Versus 2029

- 1.3.2 Syringe
- 1.3.3 Pen
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global Adalimumab Monoclonal Antibody Biosimilar Consumption

Value by Application: 2018 Versus 2022 Versus 2029

- 1.4.2 Ankylosing Spondylitis
- 1.4.3 Rheumatoid Arthritis
- 1.4.4 Crohn's Disease
- 1.4.5 Other
- 1.5 Global Adalimumab Monoclonal Antibody Biosimilar Market Size & Forecast
- 1.5.1 Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018 & 2022 & 2029)
 - 1.5.2 Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (2018-2029)
 - 1.5.3 Global Adalimumab Monoclonal Antibody Biosimilar Average Price (2018-2029)

2 MANUFACTURERS PROFILES

- 2.1 Cadila Healthcare
 - 2.1.1 Cadila Healthcare Details
 - 2.1.2 Cadila Healthcare Major Business
- 2.1.3 Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Product and Services
- 2.1.4 Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.1.5 Cadila Healthcare Recent Developments/Updates
- 2.2 Torrent Pharmaceuticals
 - 2.2.1 Torrent Pharmaceuticals Details
 - 2.2.2 Torrent Pharmaceuticals Major Business
- 2.2.3 Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Product and Services



- 2.2.4 Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.2.5 Torrent Pharmaceuticals Recent Developments/Updates
- 2.3 Amgen
 - 2.3.1 Amgen Details
 - 2.3.2 Amgen Major Business
 - 2.3.3 Amgen Adalimumab Monoclonal Antibody Biosimilar Product and Services
- 2.3.4 Amgen Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.3.5 Amgen Recent Developments/Updates
- 2.4 Boehringer Ingelheim
 - 2.4.1 Boehringer Ingelheim Details
 - 2.4.2 Boehringer Ingelheim Major Business
- 2.4.3 Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Product and Services
- 2.4.4 Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.4.5 Boehringer Ingelheim Recent Developments/Updates
- 2.5 Novartis
 - 2.5.1 Novartis Details
 - 2.5.2 Novartis Major Business
 - 2.5.3 Novartis Adalimumab Monoclonal Antibody Biosimilar Product and Services
- 2.5.4 Novartis Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.5.5 Novartis Recent Developments/Updates
- 2.6 Samsung Bioepis
 - 2.6.1 Samsung Bioepis Details
 - 2.6.2 Samsung Bioepis Major Business
- 2.6.3 Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Product and Services
- 2.6.4 Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.6.5 Samsung Bioepis Recent Developments/Updates
- 2.7 Viatris
 - 2.7.1 Viatris Details
 - 2.7.2 Viatris Major Business
 - 2.7.3 Viatris Adalimumab Monoclonal Antibody Biosimilar Product and Services
- 2.7.4 Viatris Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)



- 2.7.5 Viatris Recent Developments/Updates
- 2.8 Pfizer
 - 2.8.1 Pfizer Details
 - 2.8.2 Pfizer Major Business
 - 2.8.3 Pfizer Adalimumab Monoclonal Antibody Biosimilar Product and Services
 - 2.8.4 Pfizer Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average

Price, Revenue, Gross Margin and Market Share (2018-2023)

- 2.8.5 Pfizer Recent Developments/Updates
- 2.9 Fresenius Kabi
 - 2.9.1 Fresenius Kabi Details
 - 2.9.2 Fresenius Kabi Major Business
- 2.9.3 Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Product and Services
- 2.9.4 Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.9.5 Fresenius Kabi Recent Developments/Updates
- 2.10 Coherus
 - 2.10.1 Coherus Details
 - 2.10.2 Coherus Major Business
 - 2.10.3 Coherus Adalimumab Monoclonal Antibody Biosimilar Product and Services
- 2.10.4 Coherus Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.10.5 Coherus Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: ADALIMUMAB MONOCLONAL ANTIBODY BIOSIMILAR BY MANUFACTURER

- 3.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Manufacturer (2018-2023)
- 3.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Manufacturer (2018-2023)
- 3.3 Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Manufacturer (2018-2023)
- 3.4 Market Share Analysis (2022)
- 3.4.1 Producer Shipments of Adalimumab Monoclonal Antibody Biosimilar by Manufacturer Revenue (\$MM) and Market Share (%): 2022
- 3.4.2 Top 3 Adalimumab Monoclonal Antibody Biosimilar Manufacturer Market Share in 2022
 - 3.4.2 Top 6 Adalimumab Monoclonal Antibody Biosimilar Manufacturer Market Share



in 2022

- 3.5 Adalimumab Monoclonal Antibody Biosimilar Market: Overall Company Footprint Analysis
- 3.5.1 Adalimumab Monoclonal Antibody Biosimilar Market: Region Footprint
- 3.5.2 Adalimumab Monoclonal Antibody Biosimilar Market: Company Product Type Footprint
- 3.5.3 Adalimumab Monoclonal Antibody Biosimilar Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

- 4.1 Global Adalimumab Monoclonal Antibody Biosimilar Market Size by Region
- 4.1.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2018-2029)
- 4.1.2 Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Region (2018-2029)
- 4.1.3 Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Region (2018-2029)
- 4.2 North America Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
- 4.3 Europe Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
- 4.4 Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
- 4.5 South America Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
- 4.6 Middle East and Africa Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)

5 MARKET SEGMENT BY TYPE

- 5.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
- 5.2 Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Type (2018-2029)
- 5.3 Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Type (2018-2029)



6 MARKET SEGMENT BY APPLICATION

- 6.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
- 6.2 Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Application (2018-2029)
- 6.3 Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Application (2018-2029)

7 NORTH AMERICA

- 7.1 North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
- 7.2 North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
- 7.3 North America Adalimumab Monoclonal Antibody Biosimilar Market Size by Country
- 7.3.1 North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
- 7.3.2 North America Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
 - 7.3.3 United States Market Size and Forecast (2018-2029)
 - 7.3.4 Canada Market Size and Forecast (2018-2029)
 - 7.3.5 Mexico Market Size and Forecast (2018-2029)

8 EUROPE

- 8.1 Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
- 8.2 Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
- 8.3 Europe Adalimumab Monoclonal Antibody Biosimilar Market Size by Country
- 8.3.1 Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
- 8.3.2 Europe Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
 - 8.3.3 Germany Market Size and Forecast (2018-2029)
 - 8.3.4 France Market Size and Forecast (2018-2029)
 - 8.3.5 United Kingdom Market Size and Forecast (2018-2029)



- 8.3.6 Russia Market Size and Forecast (2018-2029)
- 8.3.7 Italy Market Size and Forecast (2018-2029)

9 ASIA-PACIFIC

- 9.1 Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
- 9.2 Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
- 9.3 Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Market Size by Region
- 9.3.1 Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2018-2029)
- 9.3.2 Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Region (2018-2029)
- 9.3.3 China Market Size and Forecast (2018-2029)
- 9.3.4 Japan Market Size and Forecast (2018-2029)
- 9.3.5 Korea Market Size and Forecast (2018-2029)
- 9.3.6 India Market Size and Forecast (2018-2029)
- 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
- 9.3.8 Australia Market Size and Forecast (2018-2029)

10 SOUTH AMERICA

- 10.1 South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
- 10.2 South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
- 10.3 South America Adalimumab Monoclonal Antibody Biosimilar Market Size by Country
- 10.3.1 South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
- 10.3.2 South America Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
 - 10.3.3 Brazil Market Size and Forecast (2018-2029)
 - 10.3.4 Argentina Market Size and Forecast (2018-2029)

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity



- by Type (2018-2029)
- 11.2 Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
- 11.3 Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Market Size by Country
- 11.3.1 Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
- 11.3.2 Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
 - 11.3.3 Turkey Market Size and Forecast (2018-2029)
 - 11.3.4 Egypt Market Size and Forecast (2018-2029)
 - 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
 - 11.3.6 South Africa Market Size and Forecast (2018-2029)

12 MARKET DYNAMICS

- 12.1 Adalimumab Monoclonal Antibody Biosimilar Market Drivers
- 12.2 Adalimumab Monoclonal Antibody Biosimilar Market Restraints
- 12.3 Adalimumab Monoclonal Antibody Biosimilar Trends Analysis
- 12.4 Porters Five Forces Analysis
 - 12.4.1 Threat of New Entrants
 - 12.4.2 Bargaining Power of Suppliers
 - 12.4.3 Bargaining Power of Buyers
 - 12.4.4 Threat of Substitutes
 - 12.4.5 Competitive Rivalry
- 12.5 Influence of COVID-19 and Russia-Ukraine War
 - 12.5.1 Influence of COVID-19
 - 12.5.2 Influence of Russia-Ukraine War

13 RAW MATERIAL AND INDUSTRY CHAIN

- 13.1 Raw Material of Adalimumab Monoclonal Antibody Biosimilar and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Adalimumab Monoclonal Antibody Biosimilar
- 13.3 Adalimumab Monoclonal Antibody Biosimilar Production Process
- 13.4 Adalimumab Monoclonal Antibody Biosimilar Industrial Chain

14 SHIPMENTS BY DISTRIBUTION CHANNEL



- 14.1 Sales Channel
 - 14.1.1 Direct to End-User
 - 14.1.2 Distributors
- 14.2 Adalimumab Monoclonal Antibody Biosimilar Typical Distributors
- 14.3 Adalimumab Monoclonal Antibody Biosimilar Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

- 16.1 Methodology
- 16.2 Research Process and Data Source
- 16.3 Disclaimer



List Of Tables

LIST OF TABLES

- Table 1. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
- Table 2. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
- Table 3. Cadila Healthcare Basic Information, Manufacturing Base and Competitors
- Table 4. Cadila Healthcare Major Business
- Table 5. Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Product and Services
- Table 6. Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 7. Cadila Healthcare Recent Developments/Updates
- Table 8. Torrent Pharmaceuticals Basic Information, Manufacturing Base and Competitors
- Table 9. Torrent Pharmaceuticals Major Business
- Table 10. Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Product and Services
- Table 11. Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 12. Torrent Pharmaceuticals Recent Developments/Updates
- Table 13. Amgen Basic Information, Manufacturing Base and Competitors
- Table 14. Amgen Major Business
- Table 15. Amgen Adalimumab Monoclonal Antibody Biosimilar Product and Services
- Table 16. Amgen Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (K Units),
- Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 17. Amgen Recent Developments/Updates
- Table 18. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
- Table 19. Boehringer Ingelheim Major Business
- Table 20. Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Product and Services
- Table 21. Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and



- Market Share (2018-2023)
- Table 22. Boehringer Ingelheim Recent Developments/Updates
- Table 23. Novartis Basic Information, Manufacturing Base and Competitors
- Table 24. Novartis Major Business
- Table 25. Novartis Adalimumab Monoclonal Antibody Biosimilar Product and Services
- Table 26. Novartis Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (K
- Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 27. Novartis Recent Developments/Updates
- Table 28. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
- Table 29. Samsung Bioepis Major Business
- Table 30. Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Product and Services
- Table 31. Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Sales
- Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 32. Samsung Bioepis Recent Developments/Updates
- Table 33. Viatris Basic Information, Manufacturing Base and Competitors
- Table 34. Viatris Major Business
- Table 35. Viatris Adalimumab Monoclonal Antibody Biosimilar Product and Services
- Table 36. Viatris Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (K Units).
- Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 37. Viatris Recent Developments/Updates
- Table 38. Pfizer Basic Information, Manufacturing Base and Competitors
- Table 39. Pfizer Major Business
- Table 40. Pfizer Adalimumab Monoclonal Antibody Biosimilar Product and Services
- Table 41. Pfizer Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (K Units),
- Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 42. Pfizer Recent Developments/Updates
- Table 43. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
- Table 44. Fresenius Kabi Major Business
- Table 45. Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Product and Services
- Table 46. Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market
- Share (2018-2023)
- Table 47. Fresenius Kabi Recent Developments/Updates



- Table 48. Coherus Basic Information, Manufacturing Base and Competitors
- Table 49. Coherus Major Business
- Table 50. Coherus Adalimumab Monoclonal Antibody Biosimilar Product and Services
- Table 51. Coherus Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (K
- Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 52. Coherus Recent Developments/Updates
- Table 53. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Manufacturer (2018-2023) & (K Units)
- Table 54. Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Manufacturer (2018-2023) & (USD Million)
- Table 55. Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Manufacturer (2018-2023) & (US\$/Unit)
- Table 56. Market Position of Manufacturers in Adalimumab Monoclonal Antibody Biosimilar, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
- Table 57. Head Office and Adalimumab Monoclonal Antibody Biosimilar Production Site of Key Manufacturer
- Table 58. Adalimumab Monoclonal Antibody Biosimilar Market: Company Product Type Footprint
- Table 59. Adalimumab Monoclonal Antibody Biosimilar Market: Company Product Application Footprint
- Table 60. Adalimumab Monoclonal Antibody Biosimilar New Market Entrants and Barriers to Market Entry
- Table 61. Adalimumab Monoclonal Antibody Biosimilar Mergers, Acquisition, Agreements, and Collaborations
- Table 62. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
- Table 63. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
- Table 64. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
- Table 65. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
- Table 66. Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Region (2018-2023) & (US\$/Unit)
- Table 67. Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Region (2024-2029) & (US\$/Unit)
- Table 68. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2023) & (K Units)



Table 69. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 70. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Type (2018-2023) & (USD Million)

Table 71. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Type (2024-2029) & (USD Million)

Table 72. Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Type (2018-2023) & (US\$/Unit)

Table 73. Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Type (2024-2029) & (US\$/Unit)

Table 74. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 75. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 76. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Application (2018-2023) & (USD Million)

Table 77. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Application (2024-2029) & (USD Million)

Table 78. Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Application (2018-2023) & (US\$/Unit)

Table 79. Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Application (2024-2029) & (US\$/Unit)

Table 80. North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 81. North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 82. North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 83. North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 84. North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2023) & (K Units)

Table 85. North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2024-2029) & (K Units)

Table 86. North America Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2023) & (USD Million)

Table 87. North America Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2024-2029) & (USD Million)

Table 88. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type



(2018-2023) & (K Units)

Table 89. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 90. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 91. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 92. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2023) & (K Units)

Table 93. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2024-2029) & (K Units)

Table 94. Europe Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2023) & (USD Million)

Table 95. Europe Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2024-2029) & (USD Million)

Table 96. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 97. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 98. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 99. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 100. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2018-2023) & (K Units)

Table 101. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2024-2029) & (K Units)

Table 102. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Region (2018-2023) & (USD Million)

Table 103. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Region (2024-2029) & (USD Million)

Table 104. South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 105. South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 106. South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 107. South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2024-2029) & (K Units)



Table 108. South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2023) & (K Units)

Table 109. South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2024-2029) & (K Units)

Table 110. South America Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2023) & (USD Million)

Table 111. South America Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2024-2029) & (USD Million)

Table 112. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 113. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 114. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 115. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 116. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2018-2023) & (K Units)

Table 117. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2024-2029) & (K Units)

Table 118. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Region (2018-2023) & (USD Million)

Table 119. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Region (2024-2029) & (USD Million)

Table 120. Adalimumab Monoclonal Antibody Biosimilar Raw Material

Table 121. Key Manufacturers of Adalimumab Monoclonal Antibody Biosimilar Raw Materials

Table 122. Adalimumab Monoclonal Antibody Biosimilar Typical Distributors

Table 123. Adalimumab Monoclonal Antibody Biosimilar Typical Customers



List Of Figures

LIST OF FIGURES

Figure 1. Adalimumab Monoclonal Antibody Biosimilar Picture

Figure 2. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 3. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Type in 2022

Figure 4. Syringe Examples

Figure 5. Pen Examples

Figure 6. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Figure 7. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Application in 2022

Figure 8. Ankylosing Spondylitis Examples

Figure 9. Rheumatoid Arthritis Examples

Figure 10. Crohn's Disease Examples

Figure 11. Other Examples

Figure 12. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value, (USD Million): 2018 & 2022 & 2029

Figure 13. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Forecast (2018-2029) & (USD Million)

Figure 14. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (2018-2029) & (K Units)

Figure 15. Global Adalimumab Monoclonal Antibody Biosimilar Average Price (2018-2029) & (US\$/Unit)

Figure 16. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Manufacturer in 2022

Figure 17. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Manufacturer in 2022

Figure 18. Producer Shipments of Adalimumab Monoclonal Antibody Biosimilar by Manufacturer Sales Quantity (\$MM) and Market Share (%): 2021

Figure 19. Top 3 Adalimumab Monoclonal Antibody Biosimilar Manufacturer (Consumption Value) Market Share in 2022

Figure 20. Top 6 Adalimumab Monoclonal Antibody Biosimilar Manufacturer (Consumption Value) Market Share in 2022

Figure 21. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Region (2018-2029)



Figure 22. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Region (2018-2029)

Figure 23. North America Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 24. Europe Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 25. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 26. South America Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 27. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 28. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Type (2018-2029)

Figure 29. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Type (2018-2029)

Figure 30. Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Type (2018-2029) & (US\$/Unit)

Figure 31. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 32. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Application (2018-2029)

Figure 33. Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Application (2018-2029) & (US\$/Unit)

Figure 34. North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Type (2018-2029)

Figure 35. North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 36. North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Country (2018-2029)

Figure 37. North America Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Country (2018-2029)

Figure 38. United States Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 39. Canada Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 40. Mexico Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 41. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market



Share by Type (2018-2029)

Figure 42. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 43. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Country (2018-2029)

Figure 44. Europe Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Country (2018-2029)

Figure 45. Germany Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 46. France Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 47. United Kingdom Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 48. Russia Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 49. Italy Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 50. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Type (2018-2029)

Figure 51. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 52. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Region (2018-2029)

Figure 53. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Region (2018-2029)

Figure 54. China Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 55. Japan Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 56. Korea Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 57. India Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 58. Southeast Asia Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 59. Australia Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 60. South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Type (2018-2029)



Figure 61. South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 62. South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Country (2018-2029)

Figure 63. South America Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Country (2018-2029)

Figure 64. Brazil Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 65. Argentina Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 66. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Type (2018-2029)

Figure 67. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 68. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Region (2018-2029)

Figure 69. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Region (2018-2029)

Figure 70. Turkey Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 71. Egypt Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 72. Saudi Arabia Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 73. South Africa Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 74. Adalimumab Monoclonal Antibody Biosimilar Market Drivers

Figure 75. Adalimumab Monoclonal Antibody Biosimilar Market Restraints

Figure 76. Adalimumab Monoclonal Antibody Biosimilar Market Trends

Figure 77. Porters Five Forces Analysis

Figure 78. Manufacturing Cost Structure Analysis of Adalimumab Monoclonal Antibody Biosimilar in 2022

Figure 79. Manufacturing Process Analysis of Adalimumab Monoclonal Antibody Biosimilar

Figure 80. Adalimumab Monoclonal Antibody Biosimilar Industrial Chain

Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors

Figure 82. Direct Channel Pros & Cons

Figure 83. Indirect Channel Pros & Cons

Figure 84. Methodology



Figure 85. Research Process and Data Source



I would like to order

Product name: Global Adalimumab Monoclonal Antibody Biosimilar Market 2023 by Manufacturers,

Regions, Type and Application, Forecast to 2029

Product link: https://marketpublishers.com/r/GDCF334A1BA5EN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GDCF334A1BA5EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

